PALO ALTO, Calif., September 15, 2022 /PRNewswire/ — Adhera Health, creators of Adhera® Precision Digital Companion™ Platformtoday announced that Luis Fernández Luque, PhD, Chief Scientific Officer of Adhera Health, presents preliminary data on supporting the mental well-being of caregivers of children being treated for growth hormone deficiency from Adhera’s first substudy.® Caring program, the company’s innovative digital health solution to support the adaptive self-management of caregivers. The data will be presented today at the European Society for Pediatric Endocrinology (ESPE 2022) in Rome Italy.
adhered to it® Care study (ClinicalTrial.gov: https://clinicaltrials.gov/ct2/show/NCT04812665) is an investigator-sponsored study supported by Merck Healthcare KGaA, Darmstadt, Germany. It was carried out in close collaboration with clinical co-investigators from the pediatric endocrinology unit of the Miguel Servet University Hospital (Zaragoza, Spain). The study followed a mixed methods approach and included two substudies that recruited caregivers of children showing suboptimal growth hormone adherence as measured by Easypod.® connected injection device (Merck Healthcare KGaA, Darmstadt, Germany).
“The results of the Adhera® The Caring study shows that improving lifestyle and mental health coping skills for caregivers of children with long-term conditions through the use of digital health tools can have a direct impact on the caregiver’s quality of life and of the child,” said Antonio de Arriba, MD, Ph.D., pediatric endocrinologist at Hospital Universitario Miguel Servet, who led the clinical interpretation of the data presented in the poster. Dr. de Arriba added that “soon, the results of the second full substudy will provide us with quantitative information about the impact of the program on health.”
The Adhera Caring program is based in Adhera® Precision Digital Companion™ platform that includes two main components: adaptable self-service content powered by a health recommendation system. The personalized theme is delivered via a mobile app and includes psycho-educational content, cognitive behavioral therapy activities for mental well-being, and personalized motivational messages. The health recommendation system is built using Artificial Intelligence (AI) to select and personalize motivational messages, making them more relevant and effective.
“We are excited about these promising results, which show that emerging digital therapeutic solutions like Adhera® Nursing is a much-needed tool in a pharmaceutical company or a doctor’s toolbox,” said Ricardo C. Berrios, CEO of Adhera Health. “Caregivers, who are often forgotten in the healthcare ecosystem, struggle with their emotional well-being and need support. The Adhera® The Caring program brings us closer to our goal of addressing unmet needs across multiple chronic conditions and impacting millions of lives.”
Antonio de Arriba, Luis Fernandez-Luque, etc. Alabama. “Supporting the mental well-being of caregivers of children on growth hormone treatment: mixed methods evaluation of the Adhera® care program”. European Society for Pediatric Endocrinology Annual Conference 2022, September 2022ESPE Abstracts (2022) 95 P1-98 – https://abstracts.eurospe.org/hrp/0095/hrp0095p1-98
About Adhera Health
Adhera Health is a Palo Alto, Californiais a company that leverages cutting-edge behavioral science research combined with an advanced personalization technology platform to create digital and human solutions that empower people with chronic illnesses to achieve lasting positive personal health outcomes, both physical and mental. Adhera Health’s solutions are based on real-world evidence that has been validated in peer-reviewed scientific journals and are deployed across multiple global clients, including Fortune 500 and small to midsize healthcare systems.
Media Relations: Ms. Päivi Salminen
+1 650 681 9664
SOURCE Adhera Health